Actinium Pharmaceuticals (ATNM) Cash from Investing Activities (2021 - 2025)
Actinium Pharmaceuticals (ATNM) has disclosed Cash from Investing Activities for 7 consecutive years, with -$93000.0 as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities changed N/A to -$93000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$104000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$104000.0 for FY2025, 845.45% down from the prior year.
- Cash from Investing Activities for Q4 2025 was -$93000.0 at Actinium Pharmaceuticals, down from -$11000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$4000.0 in Q1 2021, with the low at -$270000.0 in Q2 2022.
- Average Cash from Investing Activities over 5 years is -$63000.0, with a median of -$54000.0 recorded in 2021.
- The sharpest move saw Cash from Investing Activities plummeted 985.71% in 2023, then surged 85.53% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$68000.0 in 2021, then skyrocketed by 76.47% to -$16000.0 in 2022, then plummeted by 87.5% to -$30000.0 in 2023, then soared by 63.33% to -$11000.0 in 2024, then crashed by 745.45% to -$93000.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$93000.0, -$11000.0, and -$30000.0 for Q4 2025, Q1 2024, and Q3 2023 respectively.